PTGS2 and breast cancer: However, combined treatment with these agents resulted in a significant decrease in COX-2 and PGDS levels in PPARγ siRNA transfected MCF-7 (Figure 9(c)) and MDA-MB-231 (Figure 9(d)) breast cancer cells.